Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4315 Target Snapshot

P2Y purinoceptor 1 · SINGLE PROTEIN · Homo sapiens

1,076Compounds
226Assays
1Approved Drugs
1,350.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

P2Y purinoceptor 1 shows late clinical disease relevance led by dry eye syndrome. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P47900. Start with dry eye syndrome, then reuse UniProt P47900 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with dry eye syndrome, then reuse UniProt P47900 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
dry eye syndrome

P2Y purinoceptor 1 shows late clinical disease relevance led by dry eye syndrome. 1 linked drug remains visible in the same block.

Start review with dry eye syndrome because it currently carries late clinical support. Linked drugs include DIQUAFOSOL TETRASODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats P2Y purinoceptor 1 as ChEMBL target CHEMBL4315, mapped to UniProt P47900. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
P2Y purinoceptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4315
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P47900
P2Y purinoceptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether P2Y purinoceptor 1 is the right protein anchor across sources, using UniProt P47900 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why dry eye syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelP2Y purinoceptor 1
UniProt AccessionP47900
Component TypeProtein
Sequence Length373 aa

P2Y purinoceptor 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as P2Y purinoceptor 1, mapped to UniProt P47900. Sequence length is 373 aa.

Mapped IDP47900
Review nameP2Y purinoceptor 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

P2Y purinoceptor 1 shows late clinical disease relevance led by dry eye syndrome.

Late clinical Phase III
dry eye syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugDIQUAFOSOL TETRASODIUM
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with dry eye syndrome because it currently carries late clinical support. Linked drugs include DIQUAFOSOL TETRASODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasedry eye syndrome
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase II
1
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC50359.0
KI806.0
EC50178.0
KD7.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3314307 10.7 IC50 0.02 Preclinical
CHEMBL3287050 10.52 IC50 0.03 Preclinical
CHEMBL3314305 10.52 IC50 0.03 Preclinical
CHEMBL3287043 10.4 IC50 0.04 Preclinical
CHEMBL3287044 10.4 IC50 0.04 Preclinical
CHEMBL3314308 10.4 IC50 0.04 Preclinical
CHEMBL3314291 10.3 IC50 0.05 Preclinical
CHEMBL3287049 10.22 IC50 0.06 Preclinical
CHEMBL3263066 10.1 IC50 0.08 Preclinical
CHEMBL3287051 10.1 IC50 0.08 Preclinical
Distribution

pChEMBL Value Distribution

51
5.0
76
5.5
114
6.0
107
6.5
146
7.0
329
7.5
273
8.0
30
8.5
19
9.0
21
9.5
pChEMBL
Assay Landscape

Assay Landscape

226
Total Assays
840
Tested Compounds
2
Assay Types
Binding — 115 assays, 840 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 78 231 7.2
single protein format 26 91 7.1
assay format 6 467 7.9
cell-free format 4 50 6.0
cell membrane format 1 1 4.7
Functional — 111 assays, 188 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 60 99 7.6
cell-based format 50 89 6.2
cell membrane format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine